UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Ra'anana, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:URGN
Previous Symbol
CUSIPN/A
Phone972-9770-7601
Debt
Debt-to-Equity RatioN/A
Current Ratio12.43
Quick Ratio12.43
Price-To-Earnings
Trailing P/E Ratio-21.07
Forward P/E Ratio-10.04
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.16 million
Price / Sales75.63
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.98 per share
Price / Book9.01
Profitability
EPS (Most Recent Fiscal Year)($2.14)
Net Income$-20,000,000.00
Net Margins-4,296.08%
Return on Equity-61.06%
Return on Assets-56.96%
Miscellaneous
Employees46
Outstanding Shares13,750,000
Market Cap$639.72 million
OptionableOptionable
Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions
What is Urogen Pharma's stock symbol?
Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."
How were Urogen Pharma's earnings last quarter?
Urogen Pharma Ltd (NASDAQ:URGN) issued its quarterly earnings data on Thursday, November, 15th. The company reported ($1.28) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by $0.19. The firm earned $0.28 million during the quarter. Urogen Pharma had a negative return on equity of 61.06% and a negative net margin of 4,296.08%. View Urogen Pharma's Earnings History.
When is Urogen Pharma's next earnings date?
What price target have analysts set for URGN?
7 brokers have issued 12 month price objectives for Urogen Pharma's shares. Their predictions range from $65.00 to $77.00. On average, they expect Urogen Pharma's share price to reach $71.75 in the next twelve months. This suggests a possible upside of 59.9% from the stock's current price. View Analyst Price Targets for Urogen Pharma.
What is the consensus analysts' recommendation for Urogen Pharma?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.
Has Urogen Pharma been receiving favorable news coverage?
Media headlines about URGN stock have been trending somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Urogen Pharma earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the near term.
Who are some of Urogen Pharma's key competitors?
Some companies that are related to Urogen Pharma include Blueprint Medicines (BPMC), Endo International (ENDP), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Myokardia (MYOK), Xencor (XNCR), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX), Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), Endocyte (ECYT), Supernus Pharmaceuticals (SUPN), Pacira Pharmaceuticals (PCRX) and AnaptysBio (ANAB).
Who are Urogen Pharma's key executives?
Urogen Pharma's management team includes the folowing people:
- Mr. Ron Bentsur, CEO & Director (Age 52)
- Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 49)
- Mr. Stephen Mullennix, Chief Operating Officer
- Ms. Catherine Bechtold, Director of Corp. Communications & Investor Relations
- Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director
When did Urogen Pharma IPO?
(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
Who are Urogen Pharma's major shareholders?
Urogen Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (4.04%), Credit Suisse AG (3.05%), Citadel Advisors LLC (2.72%), Man Group plc (0.77%), BlackRock Inc. (0.75%) and Shikiar Asset Management Inc. (0.57%). View Institutional Ownership Trends for Urogen Pharma.
Which institutional investors are selling Urogen Pharma stock?
URGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Morgan Stanley, TIAA CREF Investment Management LLC and Mckinley Capital Management LLC Delaware. View Insider Buying and Selling for Urogen Pharma.
Which institutional investors are buying Urogen Pharma stock?
URGN stock was acquired by a variety of institutional investors in the last quarter, including Credit Suisse AG, Man Group plc, Citadel Advisors LLC, Point72 Asset Management L.P., Shikiar Asset Management Inc., Moody Aldrich Partners LLC, BlackRock Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Urogen Pharma.
How do I buy shares of Urogen Pharma?
Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Urogen Pharma's stock price today?
One share of URGN stock can currently be purchased for approximately $44.88.
How big of a company is Urogen Pharma?
Urogen Pharma has a market capitalization of $639.72 million and generates $8.16 million in revenue each year. The company earns $-20,000,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Urogen Pharma employs 46 workers across the globe.
What is Urogen Pharma's official website?
How can I contact Urogen Pharma?
Urogen Pharma's mailing address is 9 Ha'Ta'asiya Street, Ra'anana L3, 4365007. The company can be reached via phone at 972-9770-7601 or via email at [email protected]
MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
